Zdrowie i gospodarka · 23/08/2005

FDA Releases Draft Guidance on Observing Participants for Delayed Adverse Events in Gene Therapy Clinical Trials

The FDA has made available a draft document outlining recommendations for collecting data on delayed adverse events in gene therapy participants, which will eventually replace existing guidance on retroviral vector-based gene therapy products